SUCLG2
Succinate--CoA ligase [GDP-forming] subunit beta, mitochondrial
Also known as: SUCB2_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q96I99
- Gene
- SUCLG2
- Ensembl
- ENSG00000172340
- Chromosome
- 3
- Canonical length
- 432 aa
- Protein class
- Citric acid cycle related proteins, Enzymes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins
- Subcellular location
- Plasma membrane,Mitochondria
OverviewNCBI Gene
This gene encodes a GTP-specific beta subunit of succinyl-CoA synthetase. Succinyl-CoA synthetase catalyzes the reversible reaction involving the formation of succinyl-CoA and succinate. Alternate splicing results in multiple transcript variants. Pseudogenes of this gene are found on chromosomes 5 and 12. [provided by RefSeq, Apr 2010]
Canonical amino-acid sequenceUniProt
432 residues, UniProt reviewed canonical sequence.
>Q96I99|SUCLG2
1 MASPVAAQAG KLLRALALRP RFLAAGSQAV QLTSRRWLNL QEYQSKKLMS DNGVRVQRFF
61 VADTANEALE AAKRLNAKEI VLKAQILAGG RGKGVFNSGL KGGVHLTKDP NVVGQLAKQM
121 IGYNLATKQT PKEGVKVNKV MVAEALDISR ETYLAILMDR SCNGPVLVGS PQGGVDIEEV
181 AASNPELIFK EQIDIFEGIK DSQAQRMAEN LGFVGPLKSQ AADQITKLYN LFLKIDATQV
241 EVNPFGETPE GQVVCFDAKI NFDDNAEFRQ KDIFAMDDKS ENEPIENEAA KYDLKYIGLD
301 GNIACFVNGA GLAMATCDII FLNGGKPANF LDLGGGVKEA QVYQAFKLLT ADPKVEAILV
361 NIFGGIVNCA IIANGITKAC RELELKVPLV VRLEGTNVQE AQKILNNSGL PITSAIDLED
421 AAKKAVASVA KKLocalizationUniProt · AlphaFold · HPA
Whether an antibody against SUCLG2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.28
- Highest tissue expression
- 260 nTPM
Expression across tissuesHPA
Tissue
- liver: 260 nTPM
- colon: 159 nTPM
- skeletal muscle: 144 nTPM
- kidney: 138 nTPM
- rectum: 137 nTPM
- duodenum: 129 nTPM
Single-cell type
- parietal cells: 1,197 nCPM
- hepatocytes: 623 nCPM
- enteric transient amplifying cells: 366 nCPM
- enteric stem cells: 358 nCPM
- mucous neck cells: 334 nCPM
- colonocytes: 314 nCPM
Immune cell
- naive CD4 T-cell: 69 nTPM
- NK-cell: 68 nTPM
- naive CD8 T-cell: 53 nTPM
- total PBMC: 48 nTPM
- memory B-cell: 46 nTPM
- T-reg: 46 nTPM
Brain region
- choroid plexus: 32 nTPM
- medulla oblongata: 26 nTPM
- white matter: 24 nTPM
- thalamus: 24 nTPM
- spinal cord: 23 nTPM
- basal ganglia: 22 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.5
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.49
- DepMap mean gene effect
- -0.01
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- succinate metabolic process
- succinyl-CoA catabolic process
- succinyl-CoA metabolic process
- tricarboxylic acid cycle
Molecular functions
- ATP binding
- GDP binding
- GTP binding
- magnesium ion binding
- protein-containing complex binding
- succinate-CoA ligase (GDP-forming) activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Succinate--CoA ligase-like, beta subunit
- ATP-citrate synthase/succinyl-CoA ligase, C-terminal domain
- ATP-grasp fold, succinyl-CoA synthetase-type
- ATP-grasp fold, subdomain 1
- Succinyl-CoA synthetase-like
- Succinyl-CoA synthetase, beta subunit, conserved site
- CoA-ligase
- ATP-grasp domain
- Succinate--CoA ligase [GDP-forming] subunit beta, mitochondrial
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of SUCLG2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads SUCLG2 as an antibody target. Whether an autoantibody or antibody against SUCLG2 could matter depends on whether native SUCLG2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
SUCLG2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label SUCLG2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...